generation run 2026-05-12
59 min completedmodel pipeline-v5plan not recordedrun/379e9b0e…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
1 further caveat recorded as free text — readable on the working page
Reproduce
- inputs
- 27 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
24 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | OpenAlex | naloxone opioid antagonist mechanism | 10 | 0 | No naloxone-specific results returned |
| 2 | PubMed | naloxone pharmacokinetics bioavailability human intranasal intramuscular | 9 | 8 | All directly relevant to naloxone PK |
| 3 | PubMed | naloxone opioid receptor binding affinity pharmacology | 10 | 2 | Most directly relevant to naloxone pharmacology |
| 4 | PubChem | naloxone | 1 | 1 | Only result; matches seed data |
| 5 | PubMed | naloxone precipitated withdrawal opioid dependence adverse effects | 8 | 1 | Directly addresses naloxone-precipitated withdrawal characterization |
| 6 | PubMed · absence | naloxone history discovery synthesis Jack Fishman opioid antagonist development | 0 | 0 | No results |
| 7 | PubMed | naloxone opioid overdose reversal randomized controlled trial efficacy | 7 | 4 | Directly relevant to naloxone efficacy and take-home programs |
| 8 | PubMed | naloxone mu kappa delta opioid receptor binding affinity Ki values selectivity | 8 | 1 | Provides binding methodology validation with naloxone reference data |
| 9 | ClinicalTrials.gov | naloxone opioid overdose reversal | 10 | 5 | All directly relevant to naloxone clinical investigation |
| 10 | WebSearch | naloxone FDA approval 1971 injection Narcan 2015 intranasal 4mg 2023 OTC history regulatory | 10 | 2 | Regulatory history documented |
| 11 | WebSearch | naloxone legal status scheduling United States UK Europe Canada Australia prescription OTC 2024 | 10 | 2 | Key legal/scheduling information across jurisdictions |
| 12 | PubMed | naloxone WHO essential medicine global opioid overdose public health take-home programs | 2 | 1 | Key review of take-home naloxone programs and global context |
| 13 | PubMed | naloxone metabolism glucuronidation pharmacokinetics hepatic clearance CYP | 1 | 1 | Directly addresses naloxone metabolic pathway |
| 14 | WebSearch | naloxone discovery history 1960 Fishman Blumberg Endo Laboratories synthesis opioid antagonist | 10 | 2 | Key historical primary sources |
| 15 | Guide to PHARMACOLOGY (IUPHAR/BPS) | naloxone ligandId=1638 biology tab | 1 | 3 | Primary pharmacological binding data for naloxone at opioid receptor subtypes |
| 16 | PubMed | naloxone pulmonary edema noncardiogenic case report opioid reversal | 2 | 1 | Key safety case report for naloxone adverse effects |
| 17 | PubMed | naloxone opioid use disorder treatment evidence systematic review meta-analysis | 6 | 2 | Relevant to take-home naloxone effectiveness and public health context |
| 18 | Guide to PHARMACOLOGY (IUPHAR/BPS) | naloxone ligand ID 1638 | 1 | 3 | Critical binding affinity data for pharmacology section |
| 19 | OpenAlex | naloxone opioid overdose death prevention community distribution effectiveness | 8 | 0 | No naloxone-specific results in top-cited works |
| 20 | WebSearch | naloxone CAS number physical properties melting point solubility logP pKa DrugBank | 10 | 3 | Essential physical properties for chemical identity section |
| 21 | DrugBank · absence | — | 0 | 0 | Access blocked |
| 22 | PubMed · absence | naloxone opioid-naive effects healthy volunteers pain tolerance stress response | 0 | 0 | No results |
| 23 | Cross-reference: seed data vs published literature · absence | seed data verification for naloxone toxicity, ROA, effects, dose | 0 | 0 | Critical flags for generation agent |
| 24 | WebSearch | naloxone SMILES canonical structure PubChem DrugBank InChI key opioid antagonist | 10 | 2 | Chemical identity data for database population |
92 claims by section — every cited sentence, checked against its source
safety18 · 14 ok
Claim in safety — inconclusiveinconclusiveworking →
The principal adverse effect of naloxone is precipitated withdrawal in opioid-dependent individuals — an abrupt, severe opioid withdrawal syndrome triggered by competitive displacement of agonists from opioid receptorssupported
abrupt pharmacologically induced naloxone-precipitated withdrawal in adults with OUD. j.pbb.2026.174153
Onset occurs within 2–5 minutes of intravenous or intramuscular administration and may be delayed 15–30 minutes with intranasal formulations.supported
Tmax 15-30 min IN. s40262-024-01355-6
These effects are more pronounced with higher doses and in patients with pre-existing cardiovascular disease.supported
Concerns about severe withdrawal and pulmonary edema with high-dose naloxone. fpubh.2024.1346109
The proposed mechanism involves catecholamine-mediated volume shift to the pulmonary vasculature secondary to abrupt opioid reversalsupported
adrenergic crisis secondary to catecholamine surge causing volume shift to pulmonary vasculature. 20009666.2020.1854417
The goal of overdose reversal is restoration of adequate respiration, not precipitation of full consciousness or withdrawal — a principle that guides clinical titration practice.supported
first choice for treating opioid respiratory depression. s40262-024-01355-6
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
This interaction is the therapeutic basis for overdose reversal and is classified as low risk when appropriately managed (titrated to respiratory recovery).supported
first choice for treating opioid respiratory depression. s40262-024-01355-6
Fentanyl and its analogs may require higher or repeated doses due to greater receptor affinity and rapid redistributionsupported
Naloxone tools (2 mg IM, 4 mg IN) used by first responders can result in unacceptable loss of life following synthetic opioid OD. j.dadr.2024.100268
Fentanyl and its analogs may require higher or repeated doses due to greater receptor affinity and rapid redistributionsupported
5-mg IM and 8-mg IN naloxone are important additions. 90% due to synthetic opioids. fpubh.2024.1346109
Claim in safety — inconclusiveinconclusiveworking →
Carfentanil and nitazenes represent the extreme of this spectrum, with MOR conformations and dissociation kinetics that resist displacement at conventional naloxone doses.supported
Nitazenes require more naloxone to reverse. Radioligand experiments: nitazenes higher receptor affinity and longer dissociation half-lives than fentanyl. 2026.04.14.718203
Xylazine, an alpha-2 adrenergic agonist increasingly found as a fentanyl adulterant, is unaffected by naloxone — only the opioid component of respiratory depression is reversed, and the sedative and hemodynamic effects of xylazine persist.supported
Xylazine adulterant complicates treatment. fpubh.2024.1346109
Because naloxone is cleared via UGT glucuronidation rather than CYP enzymes, significant pharmacokinetic drug-drug interactions are not expectedsupported
Naloxone primarily cleared by UDP-glucuronosyltransferases (UGT), not CYP enzymes. s12248-020-00513-5
A pharmacokinetic interaction of clinical interest: opioid agonists increase the bioavailability of nasally administered naloxone, likely via effects on nasal mucosal blood flow.supported
Remifentanil increases bioavailability of nasally administered naloxone. s00228-021-03190-1
Known or suspected opioid dependence: Naloxone will precipitate acute withdrawal. This is not a contraindication to use in life-threatening overdose (where respiratory arrest outweighs withdrawal risk), but it mandates cautious dose titration and post-administration monitoring.supported
Initial doses 0.4-2 mg sufficient for heroin OD. s40262-024-01355-6
Cardiovascular disease: The catecholamine surge associated with abrupt opioid reversal and/or precipitated withdrawal can exacerbate hypertension, arrhythmias, and cardiac ischemia.supported
Concerns about severe withdrawal and pulmonary edema with high-dose naloxone. fpubh.2024.1346109
pharmacology15 · 10 ok
Systemic clearance is high (~91 L/hr in healthy volunteers), consistent with extensive hepatic extractionsupported
Clearance 91 L/hr. ftd.0b013e3181816214
Claim in pharmacology — inconclusiveinconclusiveworking →
Naloxone is a competitive antagonist at opioid receptors, binding with highest affinity to the mu-opioid receptor (MOR) and lower affinity to kappa-opioid (KOR) and delta-opioid (DOR) subtypessupported
Acts by competitive displacement at the mu-opioid receptor. s40262-024-01355-6
It reverses opioid effects through direct competitive displacement of agonists from receptor binding sites; the degree of displacement depends on the relative affinities and concentrations of agonist and antagonist.supported
Acts by competitive displacement at the mu-opioid receptor. s40262-024-01355-6
This latent state differs mechanistically from the "engaged" pre-activation state induced by agonists such as loperamide, providing a structural explanation for naloxone's efficacy as a pure antagonist.supported
Cryo-EM structures of MOR with naloxone or loperamide. Naloxone stalls MOR in a 'latent' state. 8 structural models, 16 cryo-EM maps capturing activation pathway intermediates. s41586-025-09677-6
Claim in pharmacology — inconclusiveinconclusiveworking →
Naloxone pharmacokinetics are route-dependent, with bioavailability ranging from approximately 4% (dilute intranasal formulations) to 100% (intravenous).supported
nasal bioavailability ~50%... Duration of 1 mg IV is ~2h. s40262-024-01355-6
Naloxone pharmacokinetics are route-dependent, with bioavailability ranging from approximately 4% (dilute intranasal formulations) to 100% (intravenous).supported
Relative bioavailability: IM 36%, IN 4%. ftd.0b013e3181816214
Claim in pharmacology — inconclusiveinconclusiveworking →
Elimination half-life ranges from 60 to 120 minutes in most studies, though one review reports a shorter estimate of approximately 33 minutes — likely reflecting a rapid distribution (beta) phase rather than terminal elimination.supported
Naloxone elimination half-life ~33 min. ajplung.00314.2024
Naloxone is primarily metabolized via UDP-glucuronosyltransferase (UGT)-mediated glucuronidation, not cytochrome P450 (CYP) enzymessupported
Naloxone primarily cleared by UDP-glucuronosyltransferases (UGT), not CYP enzymes. s12248-020-00513-5
Claim in pharmacology — inconclusiveinconclusiveworking →
Extrahepatic UGT activity in the kidney and intestine contributes to total clearancesupported
Extra-hepatic clearance based on relative UGT isoform expression in liver, kidney, intestine. s12248-020-00513-5
Physiologically based pharmacokinetic (PBPK) modeling confirms hepatic glucuronidation as the dominant clearance pathway, with model-predicted clearance values falling within 1.5-fold of observed values.supported
PBPK model verified. Systemic clearance predictions within 1.5-fold. s12248-020-00513-5
Claim in pharmacology — inconclusiveinconclusiveworking →
clinical-evidence12 · 6 ok
A randomized controlled trial (NCT02307721) in healthy volunteers established that 1.4 mg intranasal naloxone achieves systemic exposure comparable to 0.8 mg intramuscular naloxonesupported
1.4 mg IN naloxone achieves systemic exposure comparable to 0.8 mg IM naloxone. add.14552
A clinical study of 4 mg intranasal naloxone in both opioid-naive individuals and self-reported daily opioid users examined reversal of opioid-induced respiratory depression from fentanyl and sufentanilsupported
Evaluated 4 mg IN naloxone (Narcan) in reversing moderate respiratory depression induced by fentanyl and sufentanil in opioid-naive individuals and self-reported daily opioid users. aln.0000000000005931
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
A Phase 1 study in healthy volunteers confirmed the pharmacokinetic profile of concentrated naloxone nasal spray, demonstrating reliable absorption with the concentrated formulationsupported
Concentrated novel nasal spray PK: estimated IN bioavailability vs IM; early systemic exposure comparable to IM administration. add.14033
Additional PK comparison studies corroborated the 40–55% relative bioavailability of modern intranasal formulations versus intramuscular injection.supported
Absolute bioavailability of IN naloxone 55% (90% CI 43-70%). cts.12473
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Scotland's National Naloxone Programme — the first nationally coordinated take-home naloxone program — was associated with a 36% reduction in the proportion of opioid-related deaths within four weeks of prison release (2011–2013 vs. 2006–2010), with an estimated 42 fewer deaths during the post-implementation period when approximately 12,000 kits were distributed.supported
Scotland's NNP (starting Jan 2011) associated with 36% reduction in proportion of OD deaths following prison release. 42 fewer prison-release OD deaths during 2011-13 when 12,000 naloxone kits issued. add.13265
The European NalPORS cohort study (NCT05072249) is designed to evaluate take-home naloxone effectiveness across multiple European countries using mixed methods.supported
A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members. s12889-023-16445-6
Claim in clinical-evidence — inconclusiveinconclusiveworking →
pharmacokinetic-detail12 · 9 ok
This half-life mismatch creates the renarcotization hazard — re-emergence of opioid toxicity after naloxone wears offsupported
Short half-life means renarcotization risk remains. fpubh.2024.1346109
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Mean Tmax for intranasal formulations is 15–30 minutes — generally slower than IM, which has implications for time-critical overdose reversalsupported
Tmax 15-30 min IN. s40262-024-01355-6
A randomized controlled trial established that 1.4 mg intranasal naloxone achieves systemic exposure comparable to 0.8 mg intramuscular naloxone, providing the pharmacokinetic basis for intranasal dose selection.supported
1.4 mg IN naloxone achieves systemic exposure comparable to 0.8 mg IM naloxone. add.14552
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Intravenous naloxone achieves 100% bioavailability with onset of clinical effect within 1–2 minutessupported
Duration of 1 mg IV is ~2h. s40262-024-01355-6
Relative bioavailability of IM naloxone is 36–41% compared with IVsupported
Absolute bioavailability of IN naloxone 55% (90% CI 43-70%) vs 41% (90% CI 27-62%) for IM. cts.12473
Relative bioavailability of IM naloxone is 36–41% compared with IVsupported
Relative bioavailability: IM 36%, IN 4%. ftd.0b013e3181816214
Median time to peak plasma concentration (Tmax) is approximately 12 minutessupported
median Tmax IM 12 min. ftd.0b013e3181816214
A pharmacokinetic interaction study demonstrated that concurrent opioid agonist exposure (remifentanil) increases the bioavailability of nasally administered naloxone, likely through opioid-mediated reduction in nasal mucosal blood flow or alteration of mucosal permeabilitysupported
Remifentanil increases bioavailability of nasally administered naloxone. s00228-021-03190-1
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Population pharmacokinetic modeling based on healthy volunteer data and PBPK modeling converge on hepatic glucuronidation as the rate-limiting clearance pathwaysupported
Naloxone primarily cleared by UDP-glucuronosyltransferases (UGT), not CYP enzymes. PBPK model verified. s12248-020-00513-5
summary9 · 7 ok
It produces no meaningful subjective effects in opioid-naive individuals at clinical doses and has a short duration of action (30–120 minutes depending on route), a property that defines both its clinical utility and its primary limitation.supported
Half-life 60-120 min... Duration of 1 mg IV is ~2h. s40262-024-01355-6
Lewenstein at Endo Laboratories, naloxone was the first "pure" opioid antagonist — free of the partial agonist properties that limited predecessors such as nalorphinesupported
From 1915-1960 researchers sought a 'pure' antidote. s0963180121000116
FDA-approved as an injectable in 1971 and as an over-the-counter nasal spray in 2023, it is listed on the WHO Model List of Essential Medicines and has become the cornerstone of opioid overdose reversal globally.supported
New legislation permits OTC sales in some jurisdictions... >100,000 opioid OD deaths worldwide annually. s40265-019-01154-5
A 2025 cryo-EM study revealed that naloxone stalls MOR in a "latent" conformation distinct from both fully inactive and agonist-activated states, providing a structural basis for its competitive antagonismsupported
Cryo-EM structures of MOR with naloxone or loperamide. Naloxone stalls MOR in a 'latent' state. s41586-025-09677-6
Claim in summary — inconclusiveinconclusiveworking →
The primary clinical risk is precipitated withdrawal in opioid-dependent individuals, which can trigger cardiovascular stress and, rarely, noncardiogenic pulmonary edemasupported
Naloxone-induced noncardiogenic pulmonary edema is rare but reported. Proposed mechanisms include adrenergic crisis secondary to catecholamine surge causing volume shift to pulmonary vasculature. 20009666.2020.1854417
Its short half-life (60–120 minutes) creates a renarcotization hazard when reversing longer-acting opioids, and its competitive mechanism faces increasing challenge from high-affinity synthetic opioids such as carfentanil and nitazenes, which resist displacement at standard dosessupported
Nitazenes require more naloxone to reverse. Radioligand experiments: nitazenes higher receptor affinity and longer dissociation half-lives than fentanyl. 2026.04.14.718203
Its short half-life (60–120 minutes) creates a renarcotization hazard when reversing longer-acting opioids, and its competitive mechanism faces increasing challenge from high-affinity synthetic opioids such as carfentanil and nitazenes, which resist displacement at standard dosessupported
Naloxone tools (2 mg IM, 4 mg IN) used by first responders can result in unacceptable loss of life following synthetic opioid OD. j.dadr.2024.100268
Claim in summary — inconclusiveinconclusiveworking →
comparative-pharmacology7 · 5 ok
Heroin/morphine: Standard doses (0.4–0.8 mg IV/IM) are generally sufficient for reversal.supported
Initial doses 0.4-2 mg sufficient for heroin OD. s40262-024-01355-6
Methadone: Long-acting agonist (t½ ~24–36 hours); naloxone's short half-life necessitates repeated dosing or infusion. Buprenorphine has been investigated as an alternative reversal agent for methadone overdose.supported
Naloxone has short half-life, precipitates withdrawal in dependent patients, requires infusions for persistent reversal of long-acting opioids. Compared buprenorphine vs naloxone for methadone OD reversal. s13054-020-2740-y
Fentanyl and analogs: Higher doses are likely required. Fentanyl's rapid onset may leave an insufficient time window for bystander intervention.supported
fentanyl may require higher doses. s40262-024-01355-6
Fentanyl and analogs: Higher doses are likely required. Fentanyl's rapid onset may leave an insufficient time window for bystander intervention.supported
Naloxone tools (2 mg IM, 4 mg IN) used by first responders can result in unacceptable loss of life following synthetic opioid OD. j.dadr.2024.100268
Fentanyl and analogs: Higher doses are likely required. Fentanyl's rapid onset may leave an insufficient time window for bystander intervention.supported
5-mg IM and 8-mg IN naloxone are important additions. ~80,000 OIRD deaths/year in US. 90% due to synthetic opioids. fpubh.2024.1346109
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
history7 · 3 ok
Claim in history — inconclusiveinconclusiveworking →
From 1915 onward, compounds such as nalorphine demonstrated antagonist properties but retained partial agonist activity, producing dysphoria and hallucinations that restricted their utility.supported
From 1915-1960 researchers sought a 'pure' antidote. s0963180121000116
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Naloxone has been listed on the WHO Model List of Essential Medicines throughout its clinical life and is described as one of the most widely deployed emergency pharmacological agents globally.supported
>100,000 opioid OD deaths worldwide annually. IN nasal sprays approved in multiple countries. s40265-019-01154-5
Beginning in the early 2000s, the concept of take-home naloxone (THN) emerged: pre-provision of emergency naloxone kits to laypersons likely to witness opioid overdoses — peers, family members, and first responders.supported
Comprehensive review of take-home naloxone. s40265-019-01154-5
neuroscience6 · 5 ok
In opioid-dependent individuals, this abrupt blockade precipitates the dysphoria and craving characteristic of withdrawal.supported
abrupt pharmacologically induced naloxone-precipitated withdrawal in adults with OUD. j.pbb.2026.174153
Naloxone abruptly removes both signals, producing a state of acute motivational deficit (dysphoria, craving) and somatic distress that reflects the withdrawal of tonic opioid modulation across multiple neural circuits.supported
Characterized heterogeneity of opioid withdrawal comparing spontaneous withdrawal (abstinence) with abrupt pharmacologically induced naloxone-precipitated withdrawal in adults with OUD. j.pbb.2026.174153
Xylazine-opioid co-exposure: As xylazine (an alpha-2 adrenergic agonist) increasingly contaminates the illicit opioid supply, the optimal management of combined xylazine-opioid overdose — where naloxone reverses only the opioid component — remains an unresolved clinical question.supported
Xylazine adulterant complicates treatment. fpubh.2024.1346109
Long-acting formulations: Can nanoparticle-based or depot naloxone formulations provide sustained antagonist coverage sufficient to prevent renarcotization from long-acting synthetic opioids without prolonging precipitated withdrawal?supported
Novel nanoparticle naloxone formulation with 34x longer elimination half-life than high-dose free naloxone in rats. Protection against fentanyl-induced respiratory depression for up to 48h after single IM injection. acsptsci.1c00168
Naloxone restores respiratory drive by displacing agonists from these receptorssupported
Limitations for rescue of severe OIRD discussed. Naloxone elimination half-life ~33 min. ajplung.00314.2024
Claim in neuroscience — inconclusiveinconclusiveworking →
receptor-pharmacology4 · 2 ok
This pharmacological reality underlies the clinical shift toward higher-dose naloxone formulations (5 mg IM, 8 mg intranasal) in the synthetic opioid era.supported
Naloxone tools (2 mg IM, 4 mg IN) used by first responders can result in unacceptable loss of life following synthetic opioid OD. j.dadr.2024.100268
Cryo-electron microscopy (cryo-EM) of the MOR-naloxone complex reveals that naloxone occupies the orthosteric binding pocket but stalls the receptor in a "latent" conformationsupported
Cryo-EM structures of MOR with naloxone or loperamide. Naloxone stalls MOR in a 'latent' state. s41586-025-09677-6
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
chemistry1 · 0 ok
Claim in chemistry — inconclusiveinconclusiveworking →
effects-overview1 · 1 ok
The experiential profile of naloxone is entirely contingent on the opioid status of the recipient: in opioid-dependent individuals, it precipitates an abrupt withdrawal syndrome whose somatic and affective intensity exceeds spontaneous withdrawal because receptor occupancy changes instantaneously rather than declining gradually.supported
Characterized heterogeneity of opioid withdrawal comparing spontaneous withdrawal (abstinence) with abrupt pharmacologically induced naloxone-precipitated withdrawal in adults with OUD. j.pbb.2026.174153